Aug 21 2026 03:34 AM EST
Forte Biosciences Acquisition by argenx Caps Surge After Clinical Milestones
Shares of Forte Biosciences, Inc. (NASDAQ: FBRX) have climbed nearly 250% over the past three months, propelled by positive clinical trial results for FB102 and a definitive acquisition agreement with argenx SE. The deal, announced in late July at $77 per share in cash—a substantial premium to prior trading levels—has anchored the stock near its all-time high, with investors now focused on deal completion and the future of Forte’s autoimmune pipeline.
KEY FIGURES
- argenx acquisition at $77/share, valuing Forte at $2.2 billion
- Share price up 249.5% in 3 months; 52-week high $76.60
- FB102: 29.6% mean FVASI improvement in vitiligo at week 24 (p=0.020)
- FDA Fast Track for FB102 in celiac disease (May 2026)
- April 2026 equity raise: $172.5 million; Q2 cash position $198.5 million
- H1 2026 net loss $45.5 million, up from $26.9 million in H1 2025
The central catalyst for Forte’s latest move was the July 27 agreement for argenx to acquire the company at $77 per share, representing an 86% premium to the volume-weighted average price following new clinical data. The transaction, expected to close in the third quarter pending regulatory review and majority shareholder acceptance, will transfer Forte’s lead asset FB102 into argenx’s immunology pipeline. The acquisition follows a period of intense investor interest, with FBRX stock surging 266% in the 30 days prior to the deal announcement.
Clinical Progress Drives Strategic Value
Forte’s lead candidate, FB102, is a proprietary anti-CD122 monoclonal antibody targeting autoimmune and autoimmune-related diseases. In June 2025, Forte reported positive Phase 1b results in celiac disease, including a 73% improvement in a key histological ratio. The company received FDA Fast Track Designation for FB102 in celiac disease in May 2026, reflecting regulatory support and a high unmet need.
On July 9, 2026, Forte announced statistically significant improvement in facial vitiligo scores (FVASI) for FB102, with a 29.6% mean improvement at week 24 (p=0.020) and 43.2% improvement in more severe cases (p=0.006). Gains persisted 12 weeks post-treatment, supporting durable efficacy and advancing further clinical development. Multiple pivotal readouts are expected in 2026, including Phase 2 topline data in celiac disease and Phase 1b readouts in vitiligo and alopecia areata.
Financial Position Strengthened by Capital Raises
Forte reinforced its balance sheet with a $172.5 million equity raise in April 2026, ending the second quarter with $198.5 million in cash and short-term investments. This provides over 12 months of operational runway amid rising research and development expenses, which reached $20.5 million in the first quarter and $42.8 million for the first half of 2026.
Operating losses expanded in line with clinical activity, with a net loss of $45.5 million for H1 2026 compared to $26.9 million in H1 2025. The company also received $4.8 million in legal settlement payments in the first half of 2026, further supporting liquidity.
Sector Recovery and M&A Activity Reinforce Biotech Momentum
Forte’s acquisition and clinical milestones coincided with a broader recovery in the biotech sector, marked by increased M&A and licensing activity in 2026 after a challenging capital environment in 2025. The autoimmune market remains highly competitive, with larger companies such as Incyte, Pfizer, and AbbVie advancing rival therapies, including JAK inhibitors and anti-CD122 antibodies.
FB102’s differentiated mechanism and multi-indication potential attracted strategic interest from argenx, positioning Forte as a prominent innovator in organ-specific autoimmunity and supporting the premium valuation embedded in the acquisition agreement.
Risks Center on Deal Completion and Clinical Execution
The principal risk now facing Forte is the completion of the argenx acquisition. The transaction is subject to regulatory clearance, majority shareholder tender, and customary closing conditions. If the deal fails, Forte would owe a $65 million termination fee, which represents a significant portion of its cash reserves and could materially impact its future funding needs and strategic options.
Clinical and regulatory uncertainty also remain, as Forte is highly dependent on the successful development and approval of FB102. The company faces competition from established players, evolving reimbursement dynamics, and risks associated with macroeconomic volatility, regulatory shifts, and supply chain dependencies. Share dilution from recent capital raises has increased outstanding shares by over 100% since early 2025, adding longer-term financial risk if the pipeline fails to deliver.
INVESTOR WATCHLIST
- Deal completion risk: acquisition subject to regulatory and shareholder conditions; $65 million termination fee if not closed
- Single-asset dependence: FB102 clinical outcomes are central to future value
- Sector volatility: biotech sentiment and funding cycles remain unpredictable
- Competition: autoimmune market features strong rivals with similar mechanisms
- Regulatory uncertainty: evolving FDA review standards, pricing dynamics
- Share dilution: equity raises have significantly increased outstanding shares
Forte Biosciences’ recent surge reflects a combination of clinical progress, strengthened capital position, and transformative acquisition at a premium valuation. The outcome of the argenx transaction and upcoming clinical trial readouts will determine whether the company’s momentum is sustained or repriced amid sector, regulatory, and operational risks.